Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
XAY.1.1.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAY.1.1.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.25.1ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.25.1ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.25.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.25.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.25.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XADORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XADORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XADNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XADNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XADNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XABORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XABORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XABNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XABNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XABNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
CH.1.1.4ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
CH.1.1.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
CH.1.1.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CH.1.1.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CH.1.1.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
FT.4ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
FT.4ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
FT.4NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FT.4NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
FT.4NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XALORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XALORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XALNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XALNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XALNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBWORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XBWORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XBWNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBWNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBWNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.3.7ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.3.7ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.3.7NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.2.3.7NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.2.3.7NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XAY.1.1.3ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
XAY.1.1.3ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
XAY.1.1.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XAY.1.1.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XAY.1.1.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.2.19ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
BA.2.19ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
BA.2.19NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used